Literature DB >> 8710074

Axonal channelopathies: an evolving concept in the pathogenesis of peripheral nerve disorders.

L Gutmann1, L Gutmann1.   

Abstract

Abnormalities of peripheral nerve Na+ and K+ channels result in clinical manifestations unrelated to axonal degeneration or demyelination. Na+ channel blockade causes weakness and sensory loss associated with slowed conduction and decreased motor and sensory action potential amplitudes. K+ channel abnormalities result in high frequency repetitive action potentials (e.g., myokymia). Ion channel abnormalities may also play an important role in electrophysiologic changes seen in demyelinating disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8710074     DOI: 10.1212/wnl.47.1.18

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Functional characterization of the pentapeptide QYNAD on rNav1.2 channels and its NMR structure.

Authors:  R Padmashri; K S Chakrabarti; D Sahal; R Mahalakshmi; S P Sarma; S K Sikdar
Journal:  Pflugers Arch       Date:  2003-12-23       Impact factor: 3.657

2.  Single fibre electromyography in multifocal motor neuropathy with persistent conduction blocks.

Authors:  A Lagueny; G Le Masson; P Burbeaud; P Deliac
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

3.  The Influence of Chronic Inflammation on Peripheral Motor Nerve Conduction Following Spinal Cord Injury: A Randomized Clinical Trial.

Authors:  David J Allison; David A Gabriel; Panagiota Klentrou; Andrea R Josse; David S Ditor
Journal:  Top Spinal Cord Inj Rehabil       Date:  2017

4.  Towards therapeutic applications of arthropod venom k(+)-channel blockers in CNS neurologic diseases involving memory acquisition and storage.

Authors:  Christiano D C Gati; Márcia R Mortari; Elisabeth F Schwartz
Journal:  J Toxicol       Date:  2012-06-04

5.  Toward a Reasoned Classification of Diseases Using Physico-Chemical Based Phenotypes.

Authors:  Laurent Schwartz; Olivier Lafitte; Jorgelindo da Veiga Moreira
Journal:  Front Physiol       Date:  2018-02-28       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.